e-Therapeutics (ETX)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

9.80p
   
  • Change Today:
      0.20p
  • 52 Week High: 23.10
  • 52 Week Low: 8.13
  • Currency: UK Pounds
  • Shares Issued: 584.34m
  • Volume: 2,327,452
  • Market Cap: £57.26m

Growth Ratings

EPS Growth shows the relative growth of a company's earnings over the last year.

The rise in total monies receivable for goods / services sold before expenses.

1yr EPS Growth Not Available
1yr Revenue Growth
41.75% below the market average41.75% below the market average41.75% below the market average41.75% below the market average41.75% below the market average
23.53% below the sector average23.53% below the sector average23.53% below the sector average23.53% below the sector average23.53% below the sector average

Income Ratings

The percentage of the share price that a company pays out as dividends over a year.

The percentage change from the previous year in the dividend paid on each share.

Dividend Yield Not Available
1yr DPS Growth Not Available

Valuation Ratings

The share price as a ratio of revenue per share.

The share price as a ratio of net asset value.

Price Sales Ratio
87.83% above the market average87.83% above the market average87.83% above the market average87.83% above the market average87.83% above the market average
78.57% above the sector average78.57% above the sector average78.57% above the sector average78.57% above the sector average78.57% above the sector average
Price Book Ratio
38.72% below the market average38.72% below the market average38.72% below the market average38.72% below the market average38.72% below the market average
14.89% above the sector average14.89% above the sector average14.89% above the sector average14.89% above the sector average14.89% above the sector average

Performance Ratings

In percentage total change in share price over 30 days.

In percentage total change in share price over 3 months.

Price Chg 30d
80.62% below the market average80.62% below the market average80.62% below the market average80.62% below the market average80.62% below the market average
57.14% below the sector average57.14% below the sector average57.14% below the sector average57.14% below the sector average57.14% below the sector average
Price Chg 3m
90.96% below the market average90.96% below the market average90.96% below the market average90.96% below the market average90.96% below the market average
57.14% below the sector average57.14% below the sector average57.14% below the sector average57.14% below the sector average57.14% below the sector average

Technical Ratings

The Relative Strength Index measures a share price relative to itself and its recent history.

Momentum is an oscillator that measures the rate of price change.

RSI
32.94% below the market average32.94% below the market average32.94% below the market average32.94% below the market average32.94% below the market average
15.38% below the sector average15.38% below the sector average15.38% below the sector average15.38% below the sector average15.38% below the sector average
Momentum 20
42.42% below the market average42.42% below the market average42.42% below the market average42.42% below the market average42.42% below the market average
42.31% below the sector average42.31% below the sector average42.31% below the sector average42.31% below the sector average42.31% below the sector average

Management Ratings

Operating Margin is profit as a percentage of sales.

Return on capital employed measures the return from invested and borrowed capital.

Operating Margin
94.32% below the market average94.32% below the market average94.32% below the market average94.32% below the market average94.32% below the market average
65.71% below the sector average65.71% below the sector average65.71% below the sector average65.71% below the sector average65.71% below the sector average
ROCE Not Available

Profitability Ratings

Earnings per share, the company's profitability expressed on a per share basis.

Analysts' estimates of future EPS for the next 2 years.

EPS
57.63% below the market average57.63% below the market average57.63% below the market average57.63% below the market average57.63% below the market average
3.85% above the sector average3.85% above the sector average3.85% above the sector average3.85% above the sector average3.85% above the sector average
Forecast EPS Not Available

Profit/Loss Ratings

Monies produced from sales of goods and services after trade discounts, VAT, etc.

Operating Profit is the profit after deducting operating costs from gross profits.

Turnover
86.97% below the market average86.97% below the market average86.97% below the market average86.97% below the market average86.97% below the market average
60% below the sector average60% below the sector average60% below the sector average60% below the sector average60% below the sector average
Operating Profit Loss
81% below the market average81% below the market average81% below the market average81% below the market average81% below the market average
53.85% below the sector average53.85% below the sector average53.85% below the sector average53.85% below the sector average53.85% below the sector average

Balance Sheet Ratings

The difference between current assets and current liabilities.

A current asset representing the company's financial liquidity.

Assets
8.90% above the market average8.90% above the market average8.90% above the market average8.90% above the market average8.90% above the market average
41.18% above the sector average41.18% above the sector average41.18% above the sector average41.18% above the sector average41.18% above the sector average
Cash
41.60% above the market average41.60% above the market average41.60% above the market average41.60% above the market average41.60% above the market average
50.00% above the sector average50.00% above the sector average50.00% above the sector average50.00% above the sector average50.00% above the sector average

Director Deal Ratings

The cumulative amount of stocks sold by company directors over 1 year

The cumulative amount of stocks bought by company directors over 1 year

Sells 1y Not Available
Buys 1y
70.32% below the market average70.32% below the market average70.32% below the market average70.32% below the market average70.32% below the market average
93.33% below the sector average93.33% below the sector average93.33% below the sector average93.33% below the sector average93.33% below the sector average

Broker Ratings

The percentage of stockbrokers that rate the company as a Buy

The percentage of stockbrokers that rate the company as a Hold

Brokers Percent Buy Not Available
Brokers Percent Neutral Not Available

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

e-Therapeutics Market Data

Currency UK Pounds
Share Price 9.80p
Change Today 0.20p
% Change 2.08 %
52 Week High 23.10
52 Week Low 8.13
Volume 2,327,452
Shares Issued 584.34m
Market Cap £57.26m

e-Therapeutics Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
24.62% below the market average24.62% below the market average24.62% below the market average24.62% below the market average24.62% below the market average
49.02% above the sector average49.02% above the sector average49.02% above the sector average49.02% above the sector average49.02% above the sector average
Price Trend
60.62% below the market average60.62% below the market average60.62% below the market average60.62% below the market average60.62% below the market average
21.43% above the sector average21.43% above the sector average21.43% above the sector average21.43% above the sector average21.43% above the sector average
Income Not Available
Growth
15.04% below the market average15.04% below the market average15.04% below the market average15.04% below the market average15.04% below the market average
27.78% below the sector average27.78% below the sector average27.78% below the sector average27.78% below the sector average27.78% below the sector average

e-Therapeutics Dividends

No dividends found

Trades for 26-Apr-2024

Time Volume / Share Price
16:35 162,886 @ 9.80p
16:35 93,587 @ 9.80p
16:35 28,578 @ 9.80p
16:35 40,721 @ 9.80p
16:29 10,461 @ 9.80p

e-Therapeutics Key Personnel

Chair Trevor Mervyn Jones
CEO Ali Mortazavi

Top of Page